To Fully Tackle the Gang of Four, Needs-Driven R & D Is Essential

Article English OPEN
Hotez, Peter J ; Molyneux, David H ; Fenwick, Alan ; Ottesen, Eric ; Sachs, Sonia Ehrlich ; Sachs, Jeffrey D (2006)
  • Publisher: Public Library of Science
  • Journal: PLoS Medicine, volume 3, issue 6 (issn: 1549-1277, eissn: 1549-1676)
  • Related identifiers: pmc: PMC1481646, doi: 10.1371/journal.pmed.0030284
  • Subject: Correspondence and Other Communications | Medicine in Developing Countries | Infectious Diseases | Tuberculosis | Epidemiology/Public Health | wa_395 | Malaria | HIV Infection/AIDS | Hematology | Health Policy | wc_680 | Pediatrics | HIV/AIDS | Health Economics
  • References (5)

    1. Almasi EA, Stafford RS, Kravitz RL, Mansfield PR (2006) What are the public health effects of direct-to-consumer drug advertising? PLoS Med 3: e145. DOI: 10.1371/journal.pmed.0030145

    2. Heinley M (2006) Merck's actions surrounding Vioxx. PLoS Med 3: e286. DOI: 10.1371/journal.pmed.0030286

    3. Topol EJ (2004) Failing the public health-Rofecoxib, Merck, and the FDA. New Engl J Med 351: 1707-1709.

    4. Hampton T (2005) Experts point to lessons learned from controversy over rofecoxib safety. JAMA 293: 413-424.

    5. United States Food and Drug Administration (2004) Vioxx (rofecoxib) questions and answers. Available: http:⁄⁄www.fda.gov/cder/drug/ infopage/vioxx/vioxxQA.htm. Accessed 13 May 2006.

  • Metrics
    No metrics available
Share - Bookmark